Published in J Cardiovasc Electrophysiol on April 19, 2007
Cost-effectiveness of radiofrequency catheter ablation compared with antiarrhythmic drug therapy for paroxysmal atrial fibrillation. Circ Arrhythm Electrophysiol (2009) 1.33
The burden of atrial fibrillation in the Netherlands. Neth Heart J (2011) 0.94
Atrial fibrillation: the cost of illness in Sweden. Eur J Health Econ (2010) 0.91
Clinical characteristics of patients with atrial fibrillation at a tertiary care hospital in the central region of Saudi Arabia. J Family Community Med (2011) 0.82
Cost of atrial fibrillation: invasive vs non-invasive management in 2012. Curr Cardiol Rev (2012) 0.82
Sex differences in the relationship between amiodarone use and the need for permanent pacing in patients with atrial fibrillation. Arch Intern Med (2007) 0.81
Costs and clinical consequences of suboptimal atrial fibrillation management. Clinicoecon Outcomes Res (2012) 0.79
Accurate ECG diagnosis of atrial tachyarrhythmias using quantitative analysis: a prospective diagnostic and cost-effectiveness study. J Cardiovasc Electrophysiol (2010) 0.79
C-Reactive Protein Gene Polymorphisms and the Risk of Atrial Fibrillation in a Chinese Population in Taiwan. Zhonghua Minguo Xin Zang Xue Hui Za Zhi (2013) 0.78
Economics of managing atrial fibrillation: broadening the focus to include efficiency. J Cardiovasc Electrophysiol (2007) 0.78
Cost considerations in the management of atrial fibrillation - impact of dronedarone. Clinicoecon Outcomes Res (2012) 0.77
Biological Therapies for Atrial Fibrillation: Ready for Prime Time? J Cardiovasc Pharmacol (2016) 0.76
Trends in US hospitalization rates and rhythm control therapies following publication of the AFFIRM and RACE trials. J Cardiovasc Electrophysiol (2010) 0.76
Cost of AF Ablation: Where Do We Stand? Cardiol Res Pract (2011) 0.76
Is AF Ablation Cost Effective? J Atr Fibrillation (2010) 0.75
Is AF Ablation Cost Effective? J Atr Fibrillation (2010) 0.75
The Role Of Renin Angiotensin System In Atrial Fibrillation. J Atr Fibrillation (2014) 0.75
The non-anticoagulation costs of atrial fibrillation management: findings from an observational study in NHS Primary Care. Drugs Context (2014) 0.75
Association Between Atrial Fibrillation and Costs After Myocardial Infarction: A Community Study. Clin Cardiol (2015) 0.75
Evaluating the benefits of home-based management of atrial fibrillation: current perspectives. Pragmat Obs Res (2016) 0.75
A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis (1987) 174.79
A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med (2002) 16.31
Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation (2006) 11.78
A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med (2002) 8.37
Circumferential pulmonary-vein ablation for chronic atrial fibrillation. N Engl J Med (2006) 7.40
Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial. JAMA (2005) 4.60
Increasing trends in hospitalization for atrial fibrillation in the United States, 1985 through 1999: implications for primary prevention. Circulation (2003) 2.61
Assessing the direct costs of treating nonvalvular atrial fibrillation in the United States. Value Health (2006) 2.44
Costs and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillation. JAMA (2005) 2.38
Cost-effectiveness of cardioversion and antiarrhythmic therapy in nonvalvular atrial fibrillation. Ann Intern Med (1999) 2.15
Results and policy implications of the resource-based relative-value study. N Engl J Med (1988) 2.09
Cost-effectiveness of rhythm versus rate control in atrial fibrillation. Ann Intern Med (2004) 1.52
Cost of care distribution in atrial fibrillation patients: the COCAF study. Am Heart J (2004) 1.45
Cost-effectiveness of radiofrequency catheter ablation for atrial fibrillation. J Am Coll Cardiol (2006) 1.23
Impact of a practice guideline for patients with atrial fibrillation on medical resource utilization and costs. Am J Cardiol (2003) 1.22
National Hospital Discharge Survey: 2003 annual summary with detailed diagnosis and procedure data. Vital Health Stat 13 (2006) 0.95
Cost-effectiveness of therapies for patients with nonvalvular atrial fibrillation. Arch Intern Med (1998) 0.95
Incidence and predictors of myocardial infarction among patients with atrial fibrillation. J Am Coll Cardiol (2000) 0.94
Atrial fibrillation ablation leads to long-term improvement of quality of life and reduced utilization of healthcare resources. J Interv Card Electrophysiol (2003) 0.93
Variation in the utilization of antiarrhythmic drugs in patients with new-onset atrial fibrillation. Am J Cardiol (2003) 0.93
Outpatient cardioversion of atrial arrhythmias: efficacy, safety, and costs. Am Heart J (2003) 0.91
Cost analysis of catheter ablation for paroxysmal atrial fibrillation. Pacing Clin Electrophysiol (2003) 0.88
Stenting versus endarterectomy for treatment of carotid-artery stenosis. N Engl J Med (2010) 17.57
Strategies for multivessel revascularization in patients with diabetes. N Engl J Med (2012) 10.79
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med (2014) 10.54
Clinical end points in coronary stent trials: a case for standardized definitions. Circulation (2007) 10.31
Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke. N Engl J Med (2015) 9.58
Stenting and medical therapy for atherosclerotic renal-artery stenosis. N Engl J Med (2013) 8.91
Pacemaker or defibrillator surgery without interruption of anticoagulation. N Engl J Med (2013) 6.40
PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res (2009) 5.20
Dual action of neutrophil gelatinase-associated lipocalin. J Am Soc Nephrol (2007) 4.99
Trial of everolimus-eluting stents or bypass surgery for coronary disease. N Engl J Med (2015) 4.27
Warfarin use and the risk for stroke and bleeding in patients with atrial fibrillation undergoing dialysis. Circulation (2014) 3.78
Protected carotid stenting in high-surgical-risk patients: the ARCHeR results. J Vasc Surg (2006) 3.77
A critical appraisal of implantable cardioverter-defibrillator therapy for the prevention of sudden cardiac death. J Am Coll Cardiol (2008) 3.58
Discerning the incidence of symptomatic and asymptomatic episodes of atrial fibrillation before and after catheter ablation (DISCERN AF): a prospective, multicenter study. JAMA Intern Med (2013) 3.56
Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation (2006) 3.45
Health-related quality of life after transcatheter or surgical aortic valve replacement in high-risk patients with severe aortic stenosis: results from the PARTNER (Placement of AoRTic TraNscathetER Valve) Trial (Cohort A). J Am Coll Cardiol (2012) 3.29
Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. Lancet (2013) 3.17
Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial. JAMA (2007) 3.07
Rhythm versus rate control therapy and subsequent stroke or transient ischemic attack in patients with atrial fibrillation. Circulation (2012) 2.96
Detection of pulmonary vein and left atrial scar after catheter ablation with three-dimensional navigator-gated delayed enhancement MR imaging: initial experience. Radiology (2007) 2.93
Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. J Am Coll Cardiol (2012) 2.78
Hospital delays in reperfusion for ST-elevation myocardial infarction: implications when selecting a reperfusion strategy. Circulation (2006) 2.72
Concordance of physician ratings with the appropriate use criteria for coronary revascularization. J Am Coll Cardiol (2011) 2.62
A blinded, randomized, placebo-controlled trial of percutaneous laser myocardial revascularization to improve angina symptoms in patients with severe coronary disease. J Am Coll Cardiol (2005) 2.56
Cost-effectiveness of transcatheter aortic valve replacement compared with surgical aortic valve replacement in high-risk patients with severe aortic stenosis: results of the PARTNER (Placement of Aortic Transcatheter Valves) trial (Cohort A). J Am Coll Cardiol (2012) 2.56
Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents. JAMA (2007) 2.49
Assessing the direct costs of treating nonvalvular atrial fibrillation in the United States. Value Health (2006) 2.44
The frequency and cost of complications associated with coronary artery bypass grafting surgery: results from the United States Medicare program. Ann Thorac Surg (2008) 2.29
Outcomes of optimal or "stent-like"balloon angioplasty in acutemyocardial infarction: the CADILLAC trial. J Am Coll Cardiol (2003) 2.18
Impact of delay to angioplasty in patients with acute coronary syndromes undergoing invasive management: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. J Am Coll Cardiol (2010) 2.15
Troponin criteria for myocardial infarction after percutaneous coronary intervention. Arch Intern Med (2012) 2.09
The frequency and incremental cost of major complications among medicare beneficiaries receiving implantable cardioverter-defibrillators. J Am Coll Cardiol (2006) 2.05
Characteristics, management, and outcomes of 5,557 patients age > or =90 years with acute coronary syndromes: results from the CRUSADE Initiative. J Am Coll Cardiol (2007) 2.03
Preformed donor-specific antibodies and risk of antibody-mediated rejection in repeat renal transplantation. Transplantation (2014) 2.00
Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. J Thorac Cardiovasc Surg (2012) 1.99
Stent revascularization for the prevention of cardiovascular and renal events among patients with renal artery stenosis and systolic hypertension: rationale and design of the CORAL trial. Am Heart J (2006) 1.98
Comparative effectiveness of rhythm control vs rate control drug treatment effect on mortality in patients with atrial fibrillation. Arch Intern Med (2012) 1.94
Impact of multivessel disease on reperfusion success and clinical outcomes in patients undergoing primary percutaneous coronary intervention for acute myocardial infarction. Eur Heart J (2007) 1.92
State-transition modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--3. Value Health (2012) 1.90
Use of drug-eluting stents as a function of predicted benefit: clinical and economic implications of current practice. Arch Intern Med (2012) 1.89
Vascular closure devices: the second decade. J Am Coll Cardiol (2007) 1.84
Biodegradable-polymer drug-eluting stents vs. bare metal stents vs. durable-polymer drug-eluting stents: a systematic review and Bayesian approach network meta-analysis. Eur Heart J (2014) 1.82
Cost-effectiveness analysis of hypertension guidelines in South Africa: absolute risk versus blood pressure level. Circulation (2005) 1.80
Health-related quality of life after transcatheter aortic valve replacement in inoperable patients with severe aortic stenosis. Circulation (2011) 1.79
Myocardial infarction after carotid stenting and endarterectomy: results from the carotid revascularization endarterectomy versus stenting trial. Circulation (2011) 1.78
Nephrogenic fibrosing dermopathy (scleromyxedema-like illness of renal disease). J Am Acad Dermatol (2003) 1.76
The Carotid Artery Revascularization and Endarterectomy (CARE) registry: objectives, design, and implications. Catheter Cardiovasc Interv (2008) 1.75
Non-inducibility post-pulmonary vein isolation achieving exit block predicts freedom from atrial fibrillation. Eur Heart J (2005) 1.74
Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document (VARC-2). Eur J Cardiothorac Surg (2012) 1.74
Beyond restenosis: five-year clinical outcomes from second-generation coronary stent trials. Circulation (2004) 1.72
Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. Eur Heart J (2012) 1.72
Outcome of the Fidelis implantable cardioverter-defibrillator lead advisory: a report from the Canadian Heart Rhythm Society Device Advisory Committee. Heart Rhythm (2008) 1.71
Age and outcomes after carotid stenting and endarterectomy: the carotid revascularization endarterectomy versus stenting trial. Stroke (2011) 1.69
Are drug-eluting stents cost-effective? It depends on whom you ask. Circulation (2006) 1.69
Clinical predictors of arrhythmia recurrences following pulmonary vein antrum isolation for atrial fibrillation: predicting arrhythmia recurrence post-PVAI. J Cardiovasc Electrophysiol (2011) 1.68
Frequency and causes of implantable cardioverter-defibrillator therapies: is device therapy proarrhythmic? Am J Cardiol (2006) 1.68
Economic impact of same-day home discharge after uncomplicated transradial percutaneous coronary intervention and bolus-only abciximab regimen. JACC Cardiovasc Interv (2010) 1.67
APOL1 variants increase risk for FSGS and HIVAN but not IgA nephropathy. J Am Soc Nephrol (2011) 1.67
A randomized trial to evaluate the relative protection against post-percutaneous coronary intervention microvascular dysfunction, ischemia, and inflammation among antiplatelet and antithrombotic agents: the PROTECT-TIMI-30 trial. J Am Coll Cardiol (2006) 1.65
Correlates of bleeding events among moderate- to high-risk patients undergoing percutaneous coronary intervention and treated with eptifibatide: observations from the PROTECT-TIMI-30 trial. J Am Coll Cardiol (2006) 1.65
Clinical restenosis after coronary stenting: perspectives from multicenter clinical trials. J Am Coll Cardiol (2002) 1.62
Drug-eluting stents and the use of percutaneous coronary intervention among patients with class I indications for coronary artery bypass surgery undergoing index revascularization: analysis from the NCDR (National Cardiovascular Data Registry). JACC Cardiovasc Interv (2009) 1.62
Cost-effectiveness of percutaneous coronary intervention with drug eluting stents versus bypass surgery for patients with diabetes mellitus and multivessel coronary artery disease: results from the FREEDOM trial. Circulation (2012) 1.60
Survival benefit with drug-eluting stents in observational studies: fact or artifact? Circ Cardiovasc Qual Outcomes (2011) 1.59
Economic impact of angina after an acute coronary syndrome: insights from the MERLIN-TIMI 36 trial. Circ Cardiovasc Qual Outcomes (2009) 1.56
Borderline tuberculoid leprosy in a woman from the state of Georgia with armadillo exposure. J Am Acad Dermatol (2006) 1.56
Complications associated with revision of Sprint Fidelis leads: report from the Canadian Heart Rhythm Society Device Advisory Committee. Circulation (2010) 1.55
Comparison of analytic approaches for the economic evaluation of new technologies alongside multicenter clinical trials. Am Heart J (2003) 1.54
Differential mortality risk of postprocedural creatine kinase-MB elevation following successful versus unsuccessful stent procedures. J Am Coll Cardiol (2004) 1.52
Economic analysis of angiography and preemptive angioplasty to prevent hemodialysis-access thrombosis. Catheter Cardiovasc Interv (2010) 1.50
Do differences in repeat revascularization explain the antianginal benefits of bypass surgery versus percutaneous coronary intervention?: implications for future treatment comparisons. Circ Cardiovasc Qual Outcomes (2012) 1.50
Clinical predictors of Fidelis lead failure: report from the Canadian Heart Rhythm Society Device Committee. Circulation (2012) 1.49
Balancing the risks of restenosis and stent thrombosis in bare-metal versus drug-eluting stents: results of a decision analytic model. J Am Coll Cardiol (2008) 1.48
De novo thrombotic microangiopathy following treatment with sirolimus: report of two cases. Nephrol Dial Transplant (2005) 1.48
Utilization of a national network for rapid response to the Medtronic Fidelis lead advisory: the Canadian Heart Rhythm Society Device Advisory Committee. Heart Rhythm (2009) 1.48
Costs and cost-effectiveness of carotid stenting versus endarterectomy for patients at increased surgical risk: results from the SAPPHIRE trial. Catheter Cardiovasc Interv (2011) 1.48
Pancreas-kidney transplantation is associated with reduced fracture risk compared with kidney-alone transplantation in men with type 1 diabetes. Kidney Int (2013) 1.48
Costs of transradial percutaneous coronary intervention. JACC Cardiovasc Interv (2013) 1.47
Nuisance bleeding with prolonged dual antiplatelet therapy after acute myocardial infarction and its impact on health status. J Am Coll Cardiol (2013) 1.47
Sex-Specific Differences at Presentation and Outcomes Among Patients Undergoing Transcatheter Aortic Valve Replacement: A Cohort Study. Ann Intern Med (2016) 1.46
In-hospital management of atrial fibrillation: the CHADS₂ score predicts increased cost. Can J Cardiol (2011) 1.46
Repeat revascularization after contemporary percutaneous coronary intervention: an evaluation of staged, target lesion, and other unplanned revascularization procedures during the first year. Circ Cardiovasc Interv (2012) 1.46
Predicting adverse outcomes in syncope. J Emerg Med (2007) 1.45
Selecting antiplatelet therapy at the time of percutaneous intervention for an acute coronary syndrome: weighing the benefits and risks of prasugrel versus clopidogrel. Circ Cardiovasc Qual Outcomes (2012) 1.44
Stent thrombosis after successful sirolimus-eluting stent implantation. Circulation (2004) 1.43
The influence of diabetes mellitus on the practice and outcomes of percutaneous coronary intervention in the community: a report from the HCA database. J Invasive Cardiol (2003) 1.43
Claudication: exercise vs endoluminal revascularization (CLEVER) study update. J Vasc Surg (2009) 1.43